Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 21,429 | 11,060 | 8,906 | 8,195 | 7,172 |
| Cost of Goods | 4,889 | 3,220 | 3,383 | 1,826 | 3,407 |
| Gross Profit | 16,540 | 7,840 | 5,523 | 6,369 | 3,765 |
| Operating Expenses | 65,700 | 32,418 | 31,693 | 23,935 | 23,515 |
| Operating Income | -48,271 | -24,358 | -25,787 | -16,740 | -19,343 |
| Interest Expense | 1,796 | 1,798 | 1,795 | 1,791 | 4,591 |
| Other Income | -723 | 147 | 67 | 120 | 2,077 |
| Pre-tax Income | -50,790 | -26,009 | -27,515 | -18,411 | -21,857 |
| Net Income Continuous | -50,790 | -26,009 | -27,515 | -18,411 | -21,857 |
| Net Income | $-50,790 | $-26,009 | $-27,515 | $-18,411 | $-21,857 |
| EPS Basic Total Ops | -0.45 | -0.39 | -0.41 | -0.30 | -0.27 |
| EPS Basic Continuous Ops | -0.45 | -0.39 | -0.41 | -0.30 | -0.27 |
| EPS Diluted Total Ops | -0.45 | -0.39 | -0.41 | -0.30 | -0.27 |
| EPS Diluted Continuous Ops | -0.45 | -0.39 | -0.41 | -0.30 | -0.27 |
| EBITDA(a) | $-47,138 | $-23,800 | $-25,226 | $-16,152 | $-18,624 |